Quantbot Technologies LP has acquired a new stake of 3,727 shares, valued at $1.46 million, in Vertex Pharmaceuticals. Despite significant insider selling totaling $42.85 million over the past 90 days, analysts broadly recommend Vertex Pharmaceuticals as a “Moderate Buy” with an average target price of $542. The company, known for its cystic fibrosis treatments, recently reported quarterly earnings that slightly missed consensus estimates but showed a 9.5% revenue increase year-over-year.
Quantbot Technologies LP Takes $1.46 Million Position in Vertex Pharmaceuticals Incorporated $VRTX
Quantbot Technologies LP has acquired a new stake of 3,727 shares, valued at $1.46 million, in Vertex Pharmaceuticals. Despite significant insider selling totaling $42.85 million over the past 90 days, analysts broadly recommend Vertex Pharmaceuticals as a “Moderate Buy” with an average target price of $542. The company, known for its cystic fibrosis treatments, recently reported quarterly earnings that slightly missed consensus estimates but showed a 9.5% revenue increase year-over-year.